Diplopia, Blepharoptosis, and Ophthalmoplegia and 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Use

Ophthalmology

Volumn 115, Issue 12, 2008, Pages 2282-2285

  Fraunfelder, F W ^a   Richards, Amanda B ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CERIVASTATIN; DEXFENFLURAMINE; DIURETIC AGENT; ESTROGEN; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; DIABETES MELLITUS; DIPLOPIA; DISEASE ASSOCIATION; DRUG USE; ESTROGEN THERAPY; FOOD AND DRUG ADMINISTRATION; GENDER; HUMAN; HYPERTENSION; OPHTHALMOPLEGIA; PRIORITY JOURNAL; PTOSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; WORLD HEALTH ORGANIZATION;

ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; AGED, 80 AND OVER; BLEPHAROPTOSIS; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DIPLOPIA; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; OPHTHALMOPLEGIA; TIME FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WORLD HEALTH ORGANIZATION;

EID: 56549095747     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2008.08.006     Document Type: Article

References (16)

1. Bradford R.H., Shear C.L., Chremos A.N., et al. Expanded Clinical Evaluation of Lovastatin (EXCEL) Study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. Arch Intern Med 151 (1991) 43-49
2. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690
3. Ertas F.S., Ertas N.M., Gulec S., et al. Unrecognized side effect of statin treatment: unilateral blepharoptosis. Ophthal Plast Reconstr Surg 22 (2006) 222-224
4. Finsterer J., and Zuntner G. Rhabdomyolysis from simvastatin triggered by infection and muscle exertion. South Med J 98 (2005) 827-829
5. Negevesky G.J., Kolsky M.P., Laureno R., and Yau T.H. Reversible atorvastatin-associated external ophthalmoplegia, anti-acetylcholine receptor antibodies, and ataxia. Arch Ophthalmol 118 (2000) 427-428
6. Ma J., Sehgal N.L., Ayanian J.Z., and Stafford R.S. National trends in statin use by coronary heart disease risk category. PLoS Med 2 (2005) e123. http://medicine.plosjournals.org/archive/1549-1676/2/5/pdf/10.1371_journal.pmed.0020123-L.pdf Available at: http://medicine.plosjournals.org/archive/1549-1676/2/5/pdf/10.1371_journal.pmed.0020123-L.pdf. Accessed June 25, 2008
7. Edwards I.R., and Biriell C. Harmonisation in pharmacovigilance. Drug Saf 10 (1994) 93-102
8. Fraunfelder F.W. Ocular hemorrhage possibly the result of HMG-CoA reductase inhibitors. J Ocul Pharmacol Ther 20 (2004) 179-182
9. Fraunfelder F.T., and Fraunfelder F.W. Drug-Induced Ocular Side Effects. 5th ed. (2001), Butterworth-Heinemann, Boston, MA 824
10. Pasternak R.C., Smith Jr. S.C., Bairey-Merz C.N., et al. ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Circulation 106 (2002) 1024-1028
11. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 175 (2001) 486-489
12. Draeger A., Monastyrskaya K., Mohaupt M., et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia. J Pathol 210 (2006) 94-102
13. Phillips P.S., Haas R.H., Bannykh S., et al., Scripps Mercy Clinical Research Center. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137 (2002) 581-585
14. Ziajka P.E., and Wehmeier T. Peripheral neuropathy and lipid-lowering therapy. South Med J 91 (1998) 667-668
15. Kashani A., Phillips C.O., Foody J.M., et al. Risks associated with statin therapy: a systematic overview of randomized clinical trials. Circulation 114 (2006) 2788-2797
16. Soininen K., Niemi M., Kikki E., et al. Muscle symptoms associated with statins: a series of twenty patients. Basic Clin Pharmacol Toxicol 98 (2006) 51-54